BioPAL
specializes in alternatives to radiolabeled products for applications using
neutron activation (NA),
magnetic resonance imaging (MRI),
functional immunoassay technology (FIT),
and time resolved fluorescence (TRF).
BioPAL’s products are used to measure physiological processes by labeling and
tracking cells, measuring kidney function, and blood flow.
What’s New
is devoted to highlight current developments at BioPAL, such as the announcement
of scientific research agreements, company milestones, and general news of
interest to the biomedical research community.
New Product:
BioPAL proudly introduces Viahance! Viahance
dead-cell removal technology represents a major advance for the biomedical
community. Viahance's ability to remove dead cells - as well as stripped nuclei and free oligonucleotides
- from your cell culture will increase cell culture viability,
improve data quality and favorably impact downstream results. Eliminating
stripped nuclei and free oligonucleotides cleans up a cell preparation for
future molecular biology work. As important, Viahance is provided
AUTOCLAVED and does not contain foreign proteins, such as Annexin-V.
Featured Publication:
Presented at the World Conference on Regenerative Medicine. Regenerative Medicine 2009;4:S201.
Publications: Cell Labeling -
Feigenbaum GS, Lemberg L, Hare JM: Tracking cell fate with
noninvasive imaging. J Am Coll Cardio 2009;54:1627-8.
Hale SL, Dai W, Dow JS, Kloner RA: Mesenchymal stem cell
administration at coronary artery reperfusion in the rat by two delivery routes:
a quantitative
assessment. Life Sci 2008;83:511-5.
In vivo tracking of cells using a multi-detection probe. Int Soc for Stem Cell Res, 2nd Annual Meeting 2004, Abstract 233.
Quantitative in vivo tracking of labeled cells using a non-radioactive, non-optical technology. Stem Cells, Keystone Symposia 2004, Abstract 431.
MRI Contract Agents and Magnetic Nanopraticles Technology - Lee J, Hirano Y, Fukunaga
M, Silva AC, Duyn JH: On the contribution of deoxy-hemoglobin to MRI
gray-white matter phase contrast at high field. Neuroimage;49:193-8.
Molokhia SA, Jeong EK,
Higuchi WI, Li SK: Transscleral iontophoretic and intravitreal delivery of a
macromolecule: study of ocular distribution in vivo and postmortem with MRI.
Exp Eye Res 2009;88:418-25.
Chen X, Astary GW,
Sepulveda H, Mareci TH, Sarntinoranont M: Quantitative assessment of
macromolecular concentration during direct infusion into an agarose hydrogel
phantom using contrast-enhanced MRI. Magn Reson Imaging 2008;26:1433-41.
Damage to
the protein synthesizing apparatus in mouse liver in vivo by
magnetocytolysis in the presence of hepatospecific magnetic nanoparticles. J
Magn Magn Mater 2002; 248:276-285.
Neutron Activation Technology -
Method to quantify tail vein injection technique in small animals. Contemporary Topics Lab Ani Sci 2004; 43:35-38.
Neutron-activation analysis: A novel method for the assay of iohexol. J Lab Clin Med 2003; 141:106-109.
Damage to the protein synthesizing apparatus in mouse liver in vivo by magnetocytolysis in the presence of hepatospecific magnetic nanoparticles. J Magn Magn Mater 2002; 248:276-285.
Stable labeled microspheres to measure perfusion: validation of a neutron activation assay technique. Am J Physiol Heart Circ Physiol 2001; 280:H108-H116.
Hepatocyte asialoglycoprotein receptor assay using stable isotopes and neutron activation analysis. Clin Chem 2000; 46:1519-1521.
New Products:
BioPAL introduces functional immunoassay technology (FITTM)
for the measurement of kidney function.
MRI contrast agents including a unique and novel colloidal gadolinium reagent. BioPAL is the only company focused on developing new MRI contrast agents for drug discovery and research.
80 WEBSTER STREET WORCESTER, MA 01603 | (508) 770-1190